157 related articles for article (PubMed ID: 18466034)
1. Poorly differentiated gastroenteropancreatic neuroendocrine carcinoma associated with X-linked hyperimmunoglobulin M syndrome.
Malhotra RK; Li W
Arch Pathol Lab Med; 2008 May; 132(5):847-50. PubMed ID: 18466034
[TBL] [Abstract][Full Text] [Related]
2. An overview of practical issues in the diagnosis of gastroenteropancreatic neuroendocrine pathology.
Chetty R
Arch Pathol Lab Med; 2008 Aug; 132(8):1285-9. PubMed ID: 18684027
[TBL] [Abstract][Full Text] [Related]
3. Islet 1 (Isl1) expression is a reliable marker for pancreatic endocrine tumors and their metastases.
Schmitt AM; Riniker F; Anlauf M; Schmid S; Soltermann A; Moch H; Heitz PU; Klöppel G; Komminoth P; Perren A
Am J Surg Pathol; 2008 Mar; 32(3):420-5. PubMed ID: 18300808
[TBL] [Abstract][Full Text] [Related]
4. Biological and molecular aspects of gastroenteropancreatic neuroendocrine tumors.
Rindi G; Villanacci V; Ubiali A
Digestion; 2000; 62 Suppl 1():19-26. PubMed ID: 10940683
[TBL] [Abstract][Full Text] [Related]
5. The Problem of High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms: Well-Differentiated Neuroendocrine Tumors, Neuroendocrine Carcinomas, and Beyond.
Sorbye H; Baudin E; Perren A
Endocrinol Metab Clin North Am; 2018 Sep; 47(3):683-698. PubMed ID: 30098724
[TBL] [Abstract][Full Text] [Related]
6. Gastroenteropancreatic neuroendocrine neoplasms: selected pathology review and molecular updates.
Chai SM; Brown IS; Kumarasinghe MP
Histopathology; 2018 Jan; 72(1):153-167. PubMed ID: 29239038
[TBL] [Abstract][Full Text] [Related]
7. X-linked hyper-IgM syndrome associated with poorly differentiated neuroendocrine tumor presenting as obstructive jaundice secondary to extensive adenopathy.
Nagaraj N; Egwim C; Adler DG
Dig Dis Sci; 2007 Sep; 52(9):2312-6. PubMed ID: 17436099
[TBL] [Abstract][Full Text] [Related]
8. L1 is a potential marker for poorly-differentiated pancreatic neuroendocrine carcinoma.
Kaifi JT; Zinnkann U; Yekebas EF; Schurr PG; Reichelt U; Wachowiak R; Fiegel HC; Petri S; Schachner M; Izbicki JR
World J Gastroenterol; 2006 Jan; 12(1):94-8. PubMed ID: 16440424
[TBL] [Abstract][Full Text] [Related]
9. The clinical implications and biologic relevance of neurofilament expression in gastroenteropancreatic neuroendocrine neoplasms.
Schimmack S; Lawrence B; Svejda B; Alaimo D; Schmitz-Winnenthal H; Fischer L; Büchler MW; Kidd M; Modlin I
Cancer; 2012 May; 118(10):2763-75. PubMed ID: 21990041
[TBL] [Abstract][Full Text] [Related]
10. Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms.
Janson ET; Sorbye H; Welin S; Federspiel B; Grønbæk H; Hellman P; Ladekarl M; Langer SW; Mortensen J; Schalin-Jäntti C; Sundin A; Sundlöv A; Thiis-Evensen E; Knigge U
Acta Oncol; 2014 Oct; 53(10):1284-97. PubMed ID: 25140861
[TBL] [Abstract][Full Text] [Related]
11. Gastroenteropancreatic high-grade neuroendocrine carcinoma.
Sorbye H; Strosberg J; Baudin E; Klimstra DS; Yao JC
Cancer; 2014 Sep; 120(18):2814-23. PubMed ID: 24771552
[TBL] [Abstract][Full Text] [Related]
12. New and emerging syndromes due to neuroendocrine tumors.
Vinik AI; Gonzales MR
Endocrinol Metab Clin North Am; 2011 Mar; 40(1):19-63, vii. PubMed ID: 21349410
[TBL] [Abstract][Full Text] [Related]
13. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification.
Klöppel G; Perren A; Heitz PU
Ann N Y Acad Sci; 2004 Apr; 1014():13-27. PubMed ID: 15153416
[TBL] [Abstract][Full Text] [Related]
14. Staging of gastroenteropancreatic neuroendocrine tumors: how we do it based on an evidence-based approach.
McDermott S; O'Neill AC; Skehan SJ
Clin Imaging; 2013; 37(2):194-200. PubMed ID: 23465968
[TBL] [Abstract][Full Text] [Related]
15. Gastroenteropancreatic neuroendocrine tumors: multimodality imaging features with pathological correlation.
Hayashi D; Tkacz JN; Hammond S; Devenney-Cakir BC; Zaim S; Bouzegaou N; Ounadjela S; Guermazi A
Jpn J Radiol; 2011 Feb; 29(2):85-91. PubMed ID: 21359932
[TBL] [Abstract][Full Text] [Related]
16. Pathological characteristics and clinical specifications in gastroenteropancreatic neuroendocrine tumors: a study of 68 cases.
Stoica-Mustafa E; Pechianu C; Iorgescu A; Hortopan M; Dima SO; Tomulescu V; Dumitraşcu T; Ungureanu C; Andronesi D; Popescu I; Herlea V
Rom J Morphol Embryol; 2012; 53(2):351-5. PubMed ID: 22732805
[TBL] [Abstract][Full Text] [Related]
17. Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms.
Klöppel G
Endocr Relat Cancer; 2011 Oct; 18 Suppl 1():S1-16. PubMed ID: 22005112
[TBL] [Abstract][Full Text] [Related]
18. [Chromogranin A and neuroendocrine tumors].
Díaz Pérez JÁ; Currás Freixes M
Endocrinol Nutr; 2013; 60(7):386-95. PubMed ID: 23271036
[TBL] [Abstract][Full Text] [Related]
19. Transitional cell carcinoma in a patient with X-linked hyperimmunoglobulin M syndrome.
Li JS; Shyur SD; Huang RH
Pediatr Int; 2014 Dec; 56(6):911-914. PubMed ID: 25521976
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin receptor scintigraphy in liver metastasis detection from gastroenteropancreatic neuroendocrine tumors.
Schillaci O; Spanu A; Scopinaro F; Falchi A; Danieli R; Marongiu P; Pisu N; Madeddu G; Delle Fave G; Madeddu G
J Nucl Med; 2003 Mar; 44(3):359-68. PubMed ID: 12621001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
